anti-CD20 therapiesocrelizumabJNNPmultiple sclerosis
…low-up of 28.5 months1, a relevant finding given that, although anti-CD20 therapies are highly effective in suppressing focal inflammatory activity…
1articles mentioning treatments
1treatment mentions
1distinct treatments extracted
0%of mentions human-reviewed
Active filtersEntity: anti-CD20 therapies ×
anti-CD20 therapies
This treatment is selected. Its supporting articles are shown below.